TY  -  
T1  - EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies 
SN  -  /  
UR  - http://hdl.handle.net/10138/315282 
T3  -  
A1  - Kiesewetter, Barbara; Cherny, Nathan I.; Boissel, Nicolas; Cerisoli, Francesco; Dafni, Urania; de Vries, Elisabeth G. E.; Ghia, Paolo; Goekbuget, Nicola; Gonzalez-Calle, Veronica; Huntly, Brian; Jaeger, Ulrich; Latino, Nicola Jane; Douillard, Jean-Yves; Malcovati, Luca; Mateos, Maria-Victoria; Ossenkoppele, Gert J.; Porkka, Kimmo; Raderer, Markus; Ribera, Josep-Maria; Scarfo, Lydia; Wester, Ruth; Zygoura, Panagiota; Sonneveld, Pieter 
A2  -  
PB  -  
Y1  - 2020 
LA  - eng 
AB  - Objective Value frameworks in oncology have not been validated for the assessment of treatments in haematological malignancies, but to avoid overlaps and duplications it appears reasonable to build up experience on existing value frameworks, such as the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Methods Here we present the results of the first feasibility testing of the ESMO-MCBS v1.1 for haematological malignancies based on the grading of 80 contempor... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - QUALITY-OF-LIFE; CHRONIC LYMPHOCYTIC-LEUKEMIA; REFRACTORY MULTIPLE-MYELOMA; NON-HODGKIN-LYMPHOMA; LOW-DOSE CYTARABINE; STEM-CELL TRANSPLANTATION; BORTEZOMIB-MELPHALAN-PREDNISONE; OBINUTUZUMAB PLUS BENDAMUSTINE; RISK MYELODYSPLASTIC SYNDROMES; TRANSFUSION-DEPENDENT PATIENTS; 3122 Cancers 
N1  -   
PP  -  
ER  -